Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed ...

Meanwhile, if you buy the shares while they're down, you will have gotten in on the stock for a bargain -- and can maximize ...

Biotech stumbled in FY25, but we didn’t. HB Biotechnology kept its footing and delivered 23% outperformance in a tough market ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its ...

Highlighted opportunities include NANO Nuclear Energy's niche potential, Christian Dior SE's LVMH exposure, and Harrow's ...

In July 2025, global markets have been navigating a complex landscape marked by new U.S. tariff announcements and mixed economic signals, with the Nasdaq Composite Index showing resilience amidst ...

My all-weather portfolio gained 23% in H1, driven by tech, energy, and real assets amid rate cut hopes. See why I'm targeting ...

In a recent market update, Goldman Sachs raised its year-end forecast for the S&P 500 (SPX) to 6,900 by year-end, up from a ...

Simulations Plus Inc. reported lower than expected sales and reduced guidance due to cautious biopharma spending.

IPO stocks like Circle and CoreWeave have highlighted a revived U.S. IPO market. But can the rebound in valuations last?

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the Donald Trump administration's ...